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Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, affecting almost 1% 
of the world population. Although the cause of RA remains unknown, the complex interaction 
between immune mediators (cytokines and effector cells) is responsible for the joint damage that 
begins at the synovial membrane (Figure 1).  
 
Figure 1. (A) Schematic view of (1) a normal joint and (2) its changes in RA. The “radiographic joint 
space” of metacarpophalangeal joints in (3) a normal hand and (4) from a patient with established 
RA. (B) Schematic representation of events occurring in RA. 
 
Activated macrophages are critical in the pathogenesis of RA and showed specifically express a 
receptor for the vitamin folic acid (FA), folate receptor β (FRβ). This particular receptor allows 
internalization of FA-coupled cargo (Figure 2).  
 Figure 2. Schematic representation of folate mediated endocytosis. 
 
In this work we will address the potential of nanoparticles as an effective drug delivery system for 
therapies that will directly target activated macrophages. Special attention will be given to stealth 
degree of the nanoparticles as a strategy to avoid clearance by macrophages of the mononuclear 
phagocytic system (MPS) (Figure 3).  
 
Figure 3. Influence of stealth degree in specificity of folate target nanoparticles to FRβ activated 
macrophages. 
 
This work summarizes the application of FA-target nanoparticles as drug delivery systems for RA 
and proposes prospective future directions. 
